• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
MGNX

MGNX

MacroGenics, Inc.

NASDAQHealthcareBiotechnologyUS

USD4.20

+0.15 (+3.70%)

Rating:D+

Company Profile

CEO

Eric Blasius Risser

IPO Date

2013-10-10

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$4.04

Prev. Close

$4.05

Day Low

$4.00

Day High

$4.29

52W Low

$1.19

52W High

$4.64

Market Cap

$0.27B

Volume

0.63M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

18.1%

Avg Negative

3.9%

Avg Neutral

78.0%

News Feed

MacroGenics' (MGNX) CEO Scott Koenig on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·7/30/2021·↓ negative

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research·7/29/2021·↑ positive

MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call

GlobeNewsWire·7/22/2021·↓ negative

MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

GlobeNewsWire·6/16/2021·↑ positive

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNX

PRNewsWire·6/8/2021·↓ negative

Why MacroGenics Stock Is Tumbling Today

The Motley Fool·5/20/2021·↑ positive

MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting

GlobeNewsWire·5/19/2021·↑ positive

MacroGenics to Participate in Upcoming Investor Conference

GlobeNewsWire·5/19/2021·↑ positive

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·4/29/2021·↓ negative

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·4/29/2021·↑ positive